LineaRx agreement with Takis and Evvivax for cancer vaccines

Applied DNA Sciences announced yesterday that LineaRx, its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement  with Takis and Evvivax, biotechnology companies focused on the discovery and development of DNA based anti-cancer vaccines for the human and animal markets, respectively.